Programme
Wednesday, April 26th, 2023
1:15 – 1:30 pm | Welcome and introduction | ||||||||||
1:30 – 2:00 pm | Plenary 1 : GIP and Cushing, 30 years later | ||||||||||
2:00 – 3:30 pm | Session 1 : Adrenals covering Pheo/PGL
| ||||||||||
3:30 – 3:45 pm | Break | ||||||||||
3:45 – 5:15 pm | Session 2 : MTC and MEN2
|
Thursday, April 27th, 2023
8:30 – 9:00 am | Plenary 2 : USP8, 8 years later | |||||||||||||
9:00 – 10:30 am | Session 3 : Pituitary
| |||||||||||||
10:30 – 10:45 am | Break | |||||||||||||
10:45 – 12:15 pm | Session 4 : NETs
| |||||||||||||
12:15 - 1:00 pm | Oral, small molecule G-Protein Coupled Receptor agonists & antagonist in Endocrinology - Dr. Peter Trainer (UK) | |||||||||||||
1:00 – 1:45 pm | Lunch | |||||||||||||
1:45 – 3:30 pm | Session 5 : Parathyroid diseases
| |||||||||||||
3:30 – 4:00 pm | Break | |||||||||||||
4:00 – 5:00 pm | Session 6: Unmet needs and patients’ expectations
|
Friday, April 28th, 2023
8:30 – 10:00 am | Session 7: Genetics and Pediatrics
| ||||||||||
10:00 - 10:15 am | Break | ||||||||||
10:15 – 11:30 am | Session 8: MEN1 Update and guidelines
| ||||||||||
11:30 – 12:30 pm | « New tools and treatments in endocrine diseases » endorsed by the French Endocrine Society
| ||||||||||
12:30 – 1:00 pm | Best abstract (4x10 minutes oral communications) « Pancreatic imaging in MEN1 - comparison of conventional and SSTR PET-CT imaging in real-life setting » « Efficacy and Safety of Selective RET-inhibitors in Hereditary Medullary Thyroid Carcinoma: A Real-World Experience » « Treatment of parathyroid neoplasia by pharmacologic cdk4/6 Inhibition » « MEN1 « mosaicism and genetic counselling » | ||||||||||
1:10 – 1:20 pm | Conclusions - R. Thakker and F. Castinetti |